Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

Enicepatide

Drug and asset intelligence for Enicepatide with 6 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 3
Stage: Development stage unavailable

Sponsor company

Mechanism of action

GIP Agonist

Recent signals(3)

CompetitiveJune 24, 2026

Hoffmann-La Roche's Enicepatide Trial Targets Obesity and Type 2 Diabetes

A clinical study is underway to evaluate enicepatide's efficacy and safety in managing weight for obese or overweight participants with Type 2 diabetes.

CompetitiveJune 16, 2026

Roche Advances Obesity Portfolio with Promising Phase II Data on Enicepatide and Petrelintide

Roche presented late-breaking Phase II data showing significant efficacy and safety for enicepatide and petrelintide in weight management.

June 16, 2026

Roche Advances Obesity Portfolio with Promising Phase II Data for Enicepatide and Petrelintide

Roche presented late-breaking Phase II data showing significant efficacy and safety for enicepatide and petrelintide in weight management.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(3)

Topline Data

Roche — Enicepatide

June 24, 2026 · N/A

Topline Data

Roche — Enicepatide

June 16, 2026 · N/A

Topline Data

Roche — Enicepatide

June 16, 2026 · N/A

Indications

Therapeutic areas

Endocrinology →

Endocrinology · GLP-1/GIP Agonist →

GIP Agonist →

GIP Receptor Agonist and Amylin Analog →

Obesity · GLP-1/GIP Receptor Agonist and Amylin Analog →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.